These examples are illustrative, but they show the intended answer shape: practical triage, source basis, assumptions, confidence and a non-final human-review boundary.
Variation classification triageReview required
Query: We want to add a new site for finished product batch release. What variation type may apply?
Practical answer
Adding a site responsible for batch release is a Type IA IN variation under code Q.II.b.2(c)(1) where the site does not also take over batch control testing, and Q.II.b.2(c)(2) where it also tests with physicochemical or microbiological methods. It moves to Type IB under Q.II.b.2(c)(3) where the site tests a biological finished product with a biological, immunological or immunochemical procedure. The release site must be in the EU/EEA and hold a manufacturing authorisation for the proposed operations. The Commission Variations Guidelines C/2025/5045 replaced the 2013 text from 15 January 2026 and renamed the quality chapter from B to Q, so a code quoted from the 2013 annex is not valid for a new submission. Confirm the procedure route, because the same code is notified differently under MRP/DCP and the centralised procedure.
Source basis to verify
Regulation (EC) No 1234/2008, Art. 2(2), Art. 2(5) and Annex II point 1 — definition of a minor variation of Type IA and of an 'IA(IN)' immediate-notification variation.
Commission Guidelines C/2025/5045, Annex, code Q.II.b.2 — change to batch release arrangements and batch control testing of the finished product, conditions 1–5 and documentation 1–6.
Directive 2001/83/EC, Art. 40 and Art. 51 — manufacturing authorisation and Qualified Person batch certification at the release site.
Assumptions and missing information
The product is a chemical medicinal product; a biological product tested with a biological procedure at the new site shifts the change to Type IB.
The new site already holds a manufacturing authorisation covering batch release.
The exact grouping with any parallel site changes is confirmed before the notification is filed.
Confidence: High on the classification code, medium on the final type until the site role and product type are confirmed. Output is not final regulatory advice.
SmPC/PIL wording impactReview required
Query: Does adding a new warning to SmPC section 4.4 and the leaflet trigger a variation or a safety procedure?
Practical answer
A new section 4.4 warning based on new safety data is a Type II variation under code C.4. If the wording implements the outcome of a PSUR or PASS procedure or a PRAC signal recommendation, the change is filed under code C.3: Type IA IN where the agreed wording, including agreed translations, is implemented exactly, Type IB where minor assessment is still needed, and Type II where new data must be submitted. The leaflet must follow the SmPC change under Art. 59(1), and the MAH is obliged to submit the update without waiting for renewal. Whether an urgent safety restriction applies is a separate decision under Art. 22 of the variations regulation and needs the safety rationale, which is not in this question.
Source basis to verify
Commission Guidelines C/2025/5045, Annex, codes C.3 and C.4 — changes to the SmPC, labelling or leaflet implementing the outcome of a PSUR, PASS or PRAC signal procedure, and following new quality, preclinical, clinical or pharmacovigilance data.
Directive 2001/83/EC, Art. 11(4.4) and Art. 59(1) — content of SmPC section 4.4 and the requirement that the leaflet reflects the SmPC; Art. 23(2) — MAH duty to submit new information affecting the product information.
Regulation (EC) No 1234/2008, Art. 22 — urgent safety restrictions.
Assumptions and missing information
The warning is supported by new data rather than a QRD template or editorial change.
The product is not centrally authorised; for a CAP the same codes apply but the procedure runs through EMA.
The pharmacovigilance rationale is reviewed by a QPPV or delegate before submission.
Confidence: High on the classification codes, low on the procedure until the origin of the wording and the safety rationale are supplied. Output is not final regulatory advice.
Type IB dossier completeness checkReview required
Query: Check whether this Type IB package looks complete before submission.
Practical answer
A Type IB notification needs the elements listed in Annex IV of the variations regulation: the variation application form with the classification code and scope, a cover letter, the supporting documentation the guideline names for that code, and the revised product information where affected. For an MRP product the notification goes to the RMS and all CMSs at once and can only be implemented after the 30-day acknowledgement; for a centralised product it goes to EMA. The eCTD sequence is validated against the EU Module 1 validation criteria v8.2 before acceptance. Present, missing and unclear items are listed per element, with what evidence would close each gap; no completeness verdict is given without the actual documents.
Source basis to verify
Regulation (EC) No 1234/2008, Art. 9 (MRP) and Art. 16 (centralised) — Type IB notification procedure and the 30-day period; Annex IV — elements to be submitted.
Commission Guidelines C/2025/5045, Annex — documentation to be supplied for the specific classification code.
EU eCTD 3.2.2 — EU Module 1 Validation Criteria v8.2 — pass/fail and best-practice checks applied at technical validation.
Assumptions and missing information
The package contents are supplied or declared by the user; nothing is marked present on the applicant's word alone.
The change has a single classification code; grouped variations follow Annex III.
Country-specific expectations of the RMS and CMSs are checked separately.
Confidence: High for the checklist structure, low for completeness until the actual documents are attached. Output is not final regulatory advice.